Clinical Trial Search

Primary: Change in Hemoglobin A-1C From Baseline — -0.16; -0.50 percentage of glycolsylated hemoglobin — p=0.0757

Primary: Percentage of Participants With an American College of Rheumatology (ACR)20 Response at Week 24 — 24.6; 69.8; 24.6; 73.4 Percentage of Participants — p=<0.0001

Primary: Percentage of Participants Who Maintained Their Mean Hemoglobin Concentration Within +/- 1.0 Gram/Deciliter of Their Reference Hemoglobin Concentration and Between 10.0…

Primary: Change From Baseline in A1C at Week 24 — -0.33; -0.45 Percent — p=0.535

Primary: Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy — 10.97; 10.94 months — p=0.3775

Primary: Percentage of Participants Who Achieved Hemoglobin Response up to Week 24 — 79.5; 87.8 Percentage of participants

Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…

Primary: Reduction in Daily Genital Pain. — 2.4; 2.92; 3.42; 2.77 units on a scale — p=0.30

Primary: Ocular Inflammation — 96; 16 participants

Primary: Change in Hamilton Depression Scale — 17; 17.5; 20.7; 11.4 units on a scale

Primary: Safety Parameters — 142; 35; 75; 0 participants

Primary: Ocular Inflammation — 64; 19 participants

Primary: Number of Participants With Adverse Events (AEs) — 2070; 2173; 945; 1014 participants

Primary: FEV1 Peak (0-3h) Change From Baseline — 0.225; 0.395; 0.389 Litres (L) — p=<0.0001

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 95.5; 96.6 Percentage of Participants — p=<0.001